hotspot -WSS

hotspot

author：entertainment 2025-09-27 16:47:28 - browse：8265

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What Congress can do to address the rural doctor shortage

hotspot

focus

WSS

Senators: Long

The effects of a landmark ruling on DNA ownership are becoming clearer

Experts study whether long Covid risk adds up with each reinfection

The effects of a landmark ruling on DNA ownership are becoming clearer

PBM executives asked to testify by House panel

Drug for rare kidney disease narrowly misses mark in clinical trial

hotspot

hotspot

focus

Alkermes shareholders re

Senate HELP committee spars over health care workforce policies

Drug repurposing or repositioning? The language matters

Thermo Fisher plant for manufacturing gene therapies to expand

Wildfire smoke exposes gaps in outdoor worker protections

GSK’s asthma push continues as drug succeeds in Phase 3 trials

The high cost of giving birth even with insurance

Why are Kaiser Permanente staff considering a strike?

Walensky prepares to leave CDC — and Congress — behind

EpiPen alternative approval delay highlights citizen petition issue

Wikipedia

Senators: Long

AI for drug discovery: Experts on separating hype from reality

Most antidepressants don't work on kids, teens, study finds

Why are Kaiser Permanente staff considering a strike?

CDC's new outbreak response network to include Northeastern

Sepsis can kill a child within hours. Here's how hospitals are fighting back

hotspot

focus

leisure time

leisure time